AU784418B2 - Method for treating neurodegeneration - Google Patents

Method for treating neurodegeneration Download PDF

Info

Publication number
AU784418B2
AU784418B2 AU34145/01A AU3414501A AU784418B2 AU 784418 B2 AU784418 B2 AU 784418B2 AU 34145/01 A AU34145/01 A AU 34145/01A AU 3414501 A AU3414501 A AU 3414501A AU 784418 B2 AU784418 B2 AU 784418B2
Authority
AU
Australia
Prior art keywords
stroke
nefiracetam
effective amount
initiated
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34145/01A
Other languages
English (en)
Other versions
AU3414501A (en
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamilton Pharmaceuticals Inc
Original Assignee
Hamilton Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Pharmaceuticals Inc filed Critical Hamilton Pharmaceuticals Inc
Publication of AU3414501A publication Critical patent/AU3414501A/en
Assigned to HAMILTON PHARMACEUTICALS, INC. reassignment HAMILTON PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: DAIICHI PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU784418B2 publication Critical patent/AU784418B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU34145/01A 2000-02-23 2001-02-23 Method for treating neurodegeneration Ceased AU784418B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51195200A 2000-02-23 2000-02-23
US09/511952 2000-02-23
PCT/JP2001/001342 WO2001062246A1 (en) 2000-02-23 2001-02-23 Method for treating neurodegeneration

Publications (2)

Publication Number Publication Date
AU3414501A AU3414501A (en) 2001-09-03
AU784418B2 true AU784418B2 (en) 2006-03-30

Family

ID=24037094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34145/01A Ceased AU784418B2 (en) 2000-02-23 2001-02-23 Method for treating neurodegeneration

Country Status (20)

Country Link
US (2) US6423739B1 (enExample)
EP (1) EP1171123B1 (enExample)
JP (1) JP2003523385A (enExample)
KR (1) KR20010110798A (enExample)
CN (1) CN1362877A (enExample)
AR (1) AR030551A1 (enExample)
AT (1) ATE336246T1 (enExample)
AU (1) AU784418B2 (enExample)
BR (1) BR0104586A (enExample)
CA (1) CA2368352C (enExample)
DE (1) DE60122252T2 (enExample)
DK (1) DK1171123T3 (enExample)
ES (1) ES2270981T3 (enExample)
HK (1) HK1047038A1 (enExample)
ID (1) ID30377A (enExample)
IL (1) IL145799A (enExample)
MX (1) MXPA01010749A (enExample)
NO (1) NO321911B1 (enExample)
TW (1) TWI289060B (enExample)
WO (1) WO2001062246A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
RU2205631C1 (ru) * 2002-06-19 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Ноотропное средство "ноотобрил" в форме таблеток
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341790A (en) * 1979-06-13 1982-07-27 A. Nattermann & Cie. Gmbh Pyrrolidinylalkylcarboxylic acid amide derivatives, their preparation and pharmaceutical compositions containing them

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469995A (en) * 1946-07-23 1949-05-10 Schaul Martin Carl Process for the production of food preparations from potatoes and similar farinaceoustubers
US3031314A (en) * 1960-03-16 1962-04-24 Carl E Hendel Preparation of dehydrated potatoes
US3260607A (en) * 1961-02-07 1966-07-12 Canadian Patents Dev Preparation of dehydrated cooked mashed potato
US3968265A (en) * 1973-02-01 1976-07-06 American Potato Company Freeze-thaw stable, french fry potato product and process for producing the same
DE2924011C2 (de) 1979-06-13 1982-04-08 A. Nattermann & Cie GmbH, 5000 Köln Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5525058A (en) 1992-03-27 1996-06-11 American Dental Technologies, Inc. Dental treatment system
KR100232929B1 (ko) 1995-07-10 1999-12-01 히로지 코데라 가공 선재의 접속 장치
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
ES2185963T3 (es) 1996-07-30 2003-05-01 Ecolab Gmbh & Co Ohg Agente filmogeno para la proteccion contra infecciones.
EP0953356A4 (en) 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
US6211701B1 (en) 1996-12-16 2001-04-03 Rose Research, Llc Low power line switching circuit, device and method
IT1293533B1 (it) 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
AU8131198A (en) 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
KR20020015321A (ko) 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341790A (en) * 1979-06-13 1982-07-27 A. Nattermann & Cie. Gmbh Pyrrolidinylalkylcarboxylic acid amide derivatives, their preparation and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRAIN TOPOGRAPHY (1996)8(3):279-284;HIRATA ET AL. *

Also Published As

Publication number Publication date
US20020055534A1 (en) 2002-05-09
IL145799A (en) 2006-10-31
AU3414501A (en) 2001-09-03
ES2270981T3 (es) 2007-04-16
BR0104586A (pt) 2002-01-08
DK1171123T3 (da) 2006-12-04
ID30377A (id) 2001-11-29
IL145799A0 (en) 2002-07-25
WO2001062246A1 (en) 2001-08-30
KR20010110798A (ko) 2001-12-13
NO20015162L (no) 2001-12-21
AR030551A1 (es) 2003-08-27
DE60122252T2 (de) 2007-07-05
US6399650B2 (en) 2002-06-04
CN1362877A (zh) 2002-08-07
NO321911B1 (no) 2006-07-17
DE60122252D1 (de) 2006-09-28
JP2003523385A (ja) 2003-08-05
EP1171123A1 (en) 2002-01-16
US6423739B1 (en) 2002-07-23
HK1047038A1 (zh) 2003-02-07
CA2368352A1 (en) 2001-08-30
ATE336246T1 (de) 2006-09-15
TWI289060B (en) 2007-11-01
CA2368352C (en) 2009-11-10
NO20015162D0 (no) 2001-10-22
MXPA01010749A (es) 2002-08-20
EP1171123B1 (en) 2006-08-16
US20010051653A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
US20080076820A1 (en) Method for treating neurodegeneration
Malykh et al. Piracetam and piracetam-like drugs
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
RU2340342C2 (ru) СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
CA2368352C (en) Method for treating neurodegeneration
EP2073846A1 (en) Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US6284771B1 (en) Method for treating schizophrenia
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
CA2369638A1 (en) Use of osanetant in the production of medicaments used to treat mood disorders
SK1272003A3 (en) Medicaments containing cilansetron for treating non-obstipated male IBS patients
AU2004317129A1 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
US20090124606A1 (en) Composition for Treatment of Psychosis
JPH08512305A (ja) 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用
CA2531083A1 (en) Prolyl oligopeptidase inhibitors ameliorating recovery from brain trauma
WO2019023318A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA
JPH0436236A (ja) 脳神経障害及び脳循環代謝障害の改善治療剤
BG109701A (bg) Комбиниран фармацевтичен състав за инхибиране на влошаването на познавателните функции
HU190714B (en) Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid